Allozyne is categorized under Commercial Biotechnical Research in Seattle, WA and active since 2005.
Allozyne was established in 2005, and today employs 1 to 4, earning Unknown per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 5417114 by the NAICS.
If you are seeking more information, feel free to contact Meenu Chhabra, Chief Executive Officer at the company’s single location by writing to 1600 Fairview Avenue East # 300, Seattle, Washington WA 98102 or by phoning (206) 518-5700. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Allozyne |
| Contact Person: | Meenu Chhabra, Chief Executive Officer |
| Address: | 1600 Fairview Avenue East # 300, Seattle, Washington 98102 |
| Phone Number: | (206) 518-5700 |
| Website Address: | allozyne.com |
| Annual Revenue (USD): | Unknown |
| Founded: | 2005 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 5417114 |
| Share This Business: |
Allozyne was started in 2005 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 5417114. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of Unknown per annum.
Feel free to contact Meenu Chhabra, Chief Executive Officer for inquiries that concern Allozyne by calling the company number (206) 518-5700, as your correspondence is most welcome. Additionally, the physical location of the single location of Allozyne can be found at the coordinates 47.63421,-122.32685 as well as the street address 1600 Fairview Avenue East # 300 in Seattle, Washington 98102.
For its online presence, you may visit Allozyne’s website at allozyne.com and engage with its social media outlets through on Twitter and on Facebook.